GALNT5 and pancreatic neoplasm: To validate the clinical relevance of GALNT5 in PDAC, we performed immunohistochemical (IHC) staining in pancreatic tumor TMA (tissue micro-assays) containing 150 pathology-verified PDAC specimens with paired corresponding adjacent pancreatic tissues from the Ren Ji cohort and scored the TMA based on the strength and range of IHC staining.